Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Search research articles

Home
Research Domains
Biomedical And Clinical Sciences
Oncology And Carcinogenesis
Predictive And Prognostic Markers
[multi-omics Combined Test Performance Effectiveness On Opportunistic Screening Of High-risk Liver Cancer Population].

Home
Research Domains
Biomedical And Clinical Sciences
Oncology And Carcinogenesis
Predictive And Prognostic Markers
[multi-omics Combined Test Performance Effectiveness On Opportunistic Screening Of High-risk Liver Cancer Population].

Related Experiment Video

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

[Multi-omics combined test performance effectiveness on opportunistic screening of high-risk liver cancer population].

C Xie¹, B L Lin¹, H Deng¹

¹Department of Infectious Diseases, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, China.

Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology

|March 21, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

A novel multi-omics test, HCCscreen, demonstrates high sensitivity for early liver cancer detection in high-risk individuals. This advanced screening tool outperforms traditional methods like alpha-fetoprotein (AFP) and ultrasound.

Keywords:

DNA methylation Early diagnosis Gene mutation Hepatocellular carcinoma

More Related Videos

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

Related Experiment Videos

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

Area of Science:

Hepatology and Gastroenterology
Oncology
Molecular Diagnostics

Context:

Liver cancer poses a significant global health challenge, necessitating effective early screening strategies.
Current screening methods, including alpha-fetoprotein (AFP) and ultrasound, have limitations in sensitivity and specificity.
There is a critical need for advanced diagnostic tools to identify high-risk populations for liver cancer.

Purpose:

To validate the real-world performance of a multi-omics combined test (HCCscreen) for early liver cancer detection.
To compare the efficacy of HCCscreen against conventional screening methods (AFP, ultrasound, and their combinations).
To assess the correlation between multi-omics markers and disease severity in high-risk liver cancer patients.

Summary:

Tumor biomarker

The HCCscreen demonstrated high sensitivity (100%) for liver cancer and 93.8% for liver cancer and precancerous diseases, with a high negative predictive value (99.2%).

In parallel testing, HCCscreen significantly outperformed AFP and AFP combined with ultrasound, showing superior sensitivity and area under the curve (AUC).

Multi-omics markers (methylation and mutation scores) correlated significantly with disease severity and HCCscreen scores, unlike AFP levels.

Impact:

HCCscreen shows potential as a superior screening tool for identifying high-risk individuals for liver cancer in clinical practice.
This multi-omics approach may improve early detection rates, potentially leading to better patient outcomes.
The findings support the integration of advanced molecular diagnostics into routine liver cancer screening protocols.